144035-83-6
144035-83-6 結(jié)構(gòu)式
基本信息
RPR 73401
piclamilas
Piclamilast
N-(3,5-Dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide
3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide
3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide
Benzamide,3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
Skin Irrit. 2
STOT SE 3
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-12887 | 吡拉米司特 Piclamilast | 144035-83-6 | 1 mg | 490元 |
| 2026/06/05 | HY-12887 | 吡拉米司特 Piclamilast | 144035-83-6 | 5 mg | 1200元 |
| 2026/06/05 | HY-12887 | 吡拉米司特 Piclamilast | 144035-83-6 | 10 mM * 1 mLin DMSO | 1320元 |
常見問題列表
|
PDE4 16 nM (IC 50 , in pig aorta) |
PDE4 2 nM (IC 50 , in eosinophil soluble) |
PDE1 >100 μM (IC 50 ) |
PDE2 40 μM (IC 50 ) |
PDE3 >100 μM (IC 50 ) |
PDE5 14 μM (IC 50 ) |
Piclamilast (RP 73401, 1 μM, 30 min) significantly inhibits the changes in 23 genes via mechanisms involving AP-1 activation and c-Jun phosphorylation at Ser63.
Piclamilast (RP 73401) exhibits IC
50
values >100 μM, 40 μM, >100 μM, 14 μM for PDE1, PDE2, PDE3 and PDE5. Respectively.
RT-PCR
| Cell Line: | Human A549 type II lung epithelial cells. |
| Concentration: | 1 μM (H 2 O 2 200 μM). |
| Incubation Time: | 30 min. |
| Result: | Prevented H 2 O 2 -induced changes in gene expression levels in A549 cells. |
Cell Viability Assay
| Cell Line: | NB4 cells. |
| Concentration: | 30 μM. |
| Incubation Time: | 3 days. |
| Result: |
Exerted a significant enhancing effect on the induction of STAT1 observed in ATRA-treated NB4 cells.
Caused a significant increase in the number of cells expressing NBT-R activity. |
Piclamilast (RP 73401, 10 mg/kg, 30 min) alone does not affect the MST of leukemia-bearing animals. Piclamilast combined with ATRA (HY-14649) significantly more effective than ATRA alone in increasing the MST (40 days; interval 34–45 days) of leukemia-bearing animals.
| Animal Model: | SCID mice. |
| Dosage: | 10 mg/kg (combined with ATRA (HY-14649)). |
| Administration: | Injection daily. |
| Result: | Significantly more effective than ATRA alone in increasing the MST (40 days; interval 34–45 days) of leukemia-bearing animals. |